PASADENA, Calif., Oct. 22 /PRNewswire/ -- Maven Biotechnologies, LLC, an early stage biotechnology company developing a label-free multiplexing immunodiagnostic analysis system, today announced that the company will deliver a presentation at the BIOCOM Investor Conference in San Diego, California. Jeffrey C. Travis, Ph.D., Maven's President and COO, will present on Thursday, November 1, 2007 at 3:30 PM.
About Maven Biotechnologies
Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free Internal Reflection Ellipsometry) which is a complete diagnostics analysis system (instruments and disposables) that provides a next generation replacement measurement technology with significant cost benefits to the healthcare sector and technology improvements for the combined $15 B w/w immunodiagnostic markets. It offers the potential advantages of 50-75% reduced costs to both the diagnostics manufacturers and the clinical or pharma lab user. In addition, its breakthrough new way to measure immunodiagnostic tests more rapidly will positively impact point-of-care (POC) tests for emergency room screening (e.g. cardiac markers, drugs of abuse, etc.), at patient bedside, and in the O.R. Finally, it uniquely permits single to high density label-free multiplexing -- that is, when one to large numbers of tests per patient can be run at one time (e.g. tumor markers, autoimmune panels, etc.), greatly reducing costs for the patients, healthcare provider and importantly, the medical insurance industry. LFIRE(TM) is an enabling technology for more cost effective patient profiling of multiple tests for diagnosis, staging of disease and choice of targeted drug therapy, all key elements required for the medical industry's personalized medicine initiative. Most significantly, the market infrastructure for this technology already exists in the worldwide diagnostics and pharma industries and market penetration for this improved next generation, markedly cost effective, replacement measurement technology will be rapid. The Company is now planning development for the first commercial versions of LFIRE(TM), with planned market launch later in 2008.
|SOURCE Maven Biotechnologies, LLC|
Copyright©2007 PR Newswire.
All rights reserved